Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
289.43
+1.38 (0.48%)
Sep 4, 2025, 4:00 PM - Market closed
Bio-Rad Laboratories Revenue
Bio-Rad Laboratories had revenue of $651.60M in the quarter ending June 30, 2025, with 2.05% growth. This brings the company's revenue in the last twelve months to $2.55B, down -0.33% year-over-year. In the year 2024, Bio-Rad Laboratories had annual revenue of $2.57B, down -3.92%.
Revenue (ttm)
$2.55B
Revenue Growth
-0.33%
P/S Ratio
3.15
Revenue / Employee
$331,714
Employees
7,700
Market Cap
7.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.57B | -104.70M | -3.92% |
| Dec 31, 2023 | 2.67B | -131.00M | -4.67% |
| Dec 31, 2022 | 2.80B | -120.35M | -4.12% |
| Dec 31, 2021 | 2.92B | 376.92M | 14.81% |
| Dec 31, 2020 | 2.55B | 233.97M | 10.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BIO News
- 4 hours ago - Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc. - GlobeNewsWire
- 4 hours ago - Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 10 days ago - Bio-Rad's Management to Participate in Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause - Seeking Alpha
- 4 weeks ago - Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings - Benzinga
- 4 weeks ago - Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025 - Business Wire
- 4 weeks ago - Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Bio-Rad Reports Second-Quarter 2025 Financial Results - Business Wire